- Home
- NEGG vs RCEL Comparison
NEGG vs RCEL Comparison
Compare NEGG & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- RCEL
- Stock Information
- Founded
- NEGG 2001
- RCEL 2020
- Country
- NEGG United States
- RCEL United States
- Employees
- NEGG N/A
- RCEL N/A
- Industry
- NEGG Other Specialty Stores
- RCEL Medical/Dental Instruments
- Sector
- NEGG Consumer Discretionary
- RCEL Health Care
- Exchange
- NEGG Nasdaq
- RCEL Nasdaq
- Market Cap
- NEGG 180.8M
- RCEL 308.6M
- IPO Year
- NEGG 2010
- RCEL N/A
- Fundamental
- Price
- NEGG $0.45
- RCEL $12.79
- Analyst Decision
- NEGG
- RCEL Buy
- Analyst Count
- NEGG 0
- RCEL 4
- Target Price
- NEGG N/A
- RCEL $19.33
- AVG Volume (30 Days)
- NEGG 900.5K
- RCEL 117.4K
- Earning Date
- NEGG 01-14-2025
- RCEL 02-20-2025
- Dividend Yield
- NEGG N/A
- RCEL N/A
- EPS Growth
- NEGG N/A
- RCEL N/A
- EPS
- NEGG N/A
- RCEL N/A
- Revenue
- NEGG $1,391,833,000.00
- RCEL $60,040,000.00
- Revenue This Year
- NEGG $6.01
- RCEL $40.34
- Revenue Next Year
- NEGG N/A
- RCEL $52.79
- P/E Ratio
- NEGG N/A
- RCEL N/A
- Revenue Growth
- NEGG N/A
- RCEL 32.24
- 52 Week Low
- NEGG $0.39
- RCEL $7.51
- 52 Week High
- NEGG $1.32
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- NEGG 37.38
- RCEL 52.40
- Support Level
- NEGG $0.39
- RCEL $12.64
- Resistance Level
- NEGG $0.48
- RCEL $13.95
- Average True Range (ATR)
- NEGG 0.04
- RCEL 0.72
- MACD
- NEGG -0.00
- RCEL 0.02
- Stochastic Oscillator
- NEGG 26.52
- RCEL 56.23
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.